Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection
Authors
Keywords
-
Journal
Science Translational Medicine
Volume 13, Issue 609, Pages -
Publisher
American Association for the Advancement of Science (AAAS)
Online
2021-08-10
DOI
10.1126/scitranslmed.abj0847
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
- (2021) Jennifer M. Dan et al. SCIENCE
- Establishment and lineage dynamics of the SARS-CoV-2 epidemic in the UK
- (2021) Louis du Plessis et al. SCIENCE
- Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
- (2021) Wilfredo F. Garcia-Beltran et al. CELL
- SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines
- (2021) Xiaoying Shen et al. Cell Host & Microbe
- Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
- (2021) Merryn Voysey et al. LANCET
- Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
- (2021) Charlotte Manisty et al. LANCET
- Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine
- (2021) Maria Prendecki et al. LANCET
- Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
- (2021) Denis Y Logunov et al. LANCET
- Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein
- (2021) Houriiyah Tegally et al. NATURE
- BNT162b vaccines protect rhesus macaques from SARS-CoV-2
- (2021) Annette B. Vogel et al. NATURE
- SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
- (2021) Constantinos Kurt Wibmer et al. NATURE MEDICINE
- Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection
- (2021) Federico Gobbi et al. Viruses-Basel
- Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies
- (2021) Lianlian Bian et al. Expert Review of Vaccines
- Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19
- (2021) Stefania Capone et al. MOLECULAR THERAPY
- Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
- (2021) Sandile Cele et al. NATURE
- Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
- (2021) Laith J. Abu-Raddad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine
- (2021) Todd Bradley et al. NEW ENGLAND JOURNAL OF MEDICINE
- mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
- (2021) Leonidas Stamatatos et al. SCIENCE
- Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose
- (2021) Catherine J. Reynolds et al. SCIENCE
- Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection
- (2021) Nick K Jones et al. eLife
- Retrospective screening of routine respiratory samples revealed undetected community transmission and missed intervention opportunities for SARS-CoV-2 in the United Kingdom
- (2021) Joseph G. Chappell et al. JOURNAL OF GENERAL VIROLOGY
- BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
- (2021) Ugur Sahin et al. NATURE
- Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals
- (2021) Talia Kustin et al. NATURE MEDICINE
- Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19
- (2021) Yu Kaku et al. Cell Reports
- Impact of Previous Coronavirus Disease 2019 on Immune Response After a Single Dose of BNT162b2 Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine
- (2021) María Velasco et al. Open Forum Infectious Diseases
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
- (2020) Pedro M Folegatti et al. LANCET
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
- (2020) Edward E. Walsh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
- (2020) Evan J. Anderson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characterisation of SARS-CoV-2 Lentiviral Pseudotypes and Correlation between Pseudotype-Based Neutralisation Assays and Live Virus-Based Micro Neutralisation Assays
- (2020) Inesa Hyseni et al. Viruses-Basel
- Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
- (2020) Maheshi N Ramasamy et al. LANCET
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- Age-specific differences in the dynamics of protective immunity to influenza
- (2019) Sylvia Ranjeva et al. Nature Communications
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More